Timolol/dorzolamide combination therapy as initial treatment for intraocular pressure over 30 mm Hg

The design of this prospective, nonrandomized, interventional clinical trial was to determine the intraocular pressure (IOP) lowering effect of a fixed timolol/dorzolamide combination (Cosopt®) for patients with IOP over 30 mm Hg.

Saved in:
Bibliographic Details
Published inAmerican journal of ophthalmology Vol. 140; no. 6; p. 1176
Main Authors Henderer, J.D., Wilson, R.P., Moster, M.R., Myers, J., Schmidt, C., Fontanarosa, J., Steinmann, W.
Format Journal Article
LanguageEnglish
Published Chicago Elsevier Inc 01.12.2005
Elsevier Limited
Subjects
Drug therapy
Glaucoma
Online AccessGet full text

Cover

More Information
Summary:The design of this prospective, nonrandomized, interventional clinical trial was to determine the intraocular pressure (IOP) lowering effect of a fixed timolol/dorzolamide combination (Cosopt®) for patients with IOP over 30 mm Hg.
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2005.10.033